Related Experiment Videos
A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients
D Chang1, L Liem, M Malogolowkin
1Division of Pharmacy, Childrens Hospital Los Angeles, CA 90027.
Insights
Pediatric cancer patients require higher vancomycin (VANC) doses than standard to achieve therapeutic serum concentrations (SVCs). A Bayesian forecasting program accurately predicted VANC levels, aiding dosage adjustments in this population.
Area of Science:
- Pharmacology
- Pediatric Oncology
- Clinical Pharmacy
Background:
- Vancomycin is crucial for treating serious infections in pediatric cancer patients.
- Standard vancomycin dosing may not achieve therapeutic serum concentrations in this vulnerable group.
- Accurate pharmacokinetic monitoring is essential for optimizing vancomycin therapy.
Purpose of the Study:
- To evaluate vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
- To assess the predictive performance of a two-compartment Bayesian forecasting program.
- To determine optimal vancomycin dosage regimens for achieving target serum concentrations.
Main Methods:
- Prospective pharmacokinetic study in 28 pediatric cancer patients (9 months to 13 years).
- Administration of vancomycin and monitoring of serum vancomycin concentrations (SVCs).
- Evaluation of a two-compartment Bayesian forecasting program for predicting SVCs.
Main Results:
- A mean daily dosage of 75 mg/kg/day was needed to achieve target peak SVCs (23.1 mg/L) and trough SVCs (6.2 mg/L).
- Mean vancomycin clearance was 0.153 L/hr/kg, volume of distribution was 0.63 L/kg, and half-life was 2.95 hours.
- The Bayesian program accurately predicted peak SVCs (prediction error: -1.2 mg/L) and trough SVCs (prediction error: -0.1 mg/L).
Conclusions:
- Pediatric cancer patients with normal renal function require significantly higher vancomycin doses than the standard 40 mg/kg/day.
- The Bayesian forecasting program demonstrates reliable performance in predicting vancomycin levels for dosage adjustments.
- Optimized vancomycin dosing is critical for effective treatment and improved outcomes in pediatric cancer patients.
Abstract:
Pharmacokinetics of vancomycin and dosage requirements were evaluated prospectively in 28 pediatric cancer patients 9 months to 13 years of age. The predictive performance of a two-compartment Bayesian forecasting program was also evaluated. A mean (+/- SD) daily dosage of 75 +/- 22 mg/kg/day was necessary to attain a mean peak serum vancomycin concentration (SVC) of 23.1 +/- 5.8 mg/liter and a mean trough SVC of 6.2 +/- 2.3 mg/liter. Mean vancomycin clearance, volume of distribution and serum half-life were 0.153 +/- 0.033 liter/hour/kg, 0.63 +/- 0.08 liter/kg and 2.95 +/- 0.48 hours. Final peak SVCs, which reflected the last dosage regimens received, were predicted with minimal bias (mean prediction error, -1.2 mg/liter) and accurate precision (root mean-squared prediction error, 2.0 mg/liter) whereas trough SVCs were predicted with even smaller bias (mean prediction error, -0.1 mg/liter) and greater precision (root mean-squared prediction error, 0.8 mg/liter). This study showed that pediatric cancer patients with normal renal function required vancomycin dosage regimens substantially greater than the standard 40 mg/kg/day to attain the desired SVCs.